Patents by Inventor Nicolas Wiernsperger

Nicolas Wiernsperger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating diabetic retinopathy with pericyte apoptosis inhibitors
    Patent number: 8119609
    Abstract: A method of preventing or treating diabetic retinopathy is disclosed including administering to a mammal a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Also disclosed is a pharmaceutical composition which treats and/or prevents diabetic retinopathy comprising as an active agent a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: February 21, 2012
    Assignees: Merck Sante, INSERM
    Inventors: Marc Lecomte, Ulriche Denis, Clarisse Paget, Nicolas Wiernsperger, Michel Lagarde
  • Gm3 Synthase as a Therapeutic Target in Microvascular Complications of Diabetes
    Publication number: 20070224200
    Abstract: The present invention relates to the use of an inhibitor of the expression or activity of the GM3 synthase gene for the treatment of microvascular complications of diabetes, and to a method of screening compounds useful in the treatment and/or prevention of these complications.
    Type: Application
    Filed: April 7, 2005
    Publication date: September 27, 2007
    Inventors: Samer Elbawab, Elodie Masson, Daniel Ruggiero, Nicolas Wiernsperger, Michel Lagarde, Lysiane Troncy
  • Novel pharmaceutical compositions having an antidiabetic action, and process for their preparation
    Publication number: 20040039031
    Abstract: The present invention relates to the field of therapeutic chemistry and more particularly to the preparation of novel medicinal products for treating diabetes. Specifically, a subject of the invention is novel antidiabetic medicinal products consisting of a combination of two active principles that are effective via the oral route, at subliminal doses, formed from an antidiabetic biguanide and an antidiabetic sulfonamide, in combination or as a mixture with one or more inert, pharmaceutically acceptable excipients. The invention also relates to a process for the preparation of such medicinal products formed from a biguanide and a sulfonamide.
    Type: Application
    Filed: May 21, 2003
    Publication date: February 26, 2004
    Inventors: Nathalie Cugnardey, Nicolas Wiernsperger
  • Methods and compositions of treating and/or preventing diabetic retinopathy with pericyte apoptosis inhibitors
    Publication number: 20030216290
    Abstract: A method of preventing or treating diabetic retinopathy is disclosed including administering to a mammal a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Also disclosed is a pharmaceutical composition which treats and/or prevents diabetic retinopathy comprising as an active agent a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 23, 2003
    Publication date: November 20, 2003
    Applicants: Merck Sante, a corporation of France, INSERM, a corporation of France
    Inventors: Marc Lecomte, Ulriche Denis, Clarisse Paget, Nicolas Wiernsperger, Michel Lagarde
  • Triazepinones, process for their preparation and their therapeutic application
    Patent number: 6258804
    Abstract: Described are compound of the formula (I) defined herein which are useful, for example, in the treatment of diabetes. Also described is a method for preparing the compounds.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: July 10, 2001
    Assignee: Merck Patent GmbH
    Inventors: Daniel Ruggiero, Nicolas Wiernsperger, Gérard Patereau, Gérard Moinet